On the road to precision cancer medicine: Analysis of genomic biomarker actionability in 439 patients

Molecular Cancer Therapeutics

Volumn 14, Issue 6, 2015, Pages 1488-1494

  Schwaederle, Maria ^a   Daniels, Gregory A ^a   Piccioni, David E ^a   Fanta, Paul T ^a   Schwab, Richard B ^a   Shimabukuro, Kelly A ^a   Parker, Barbara A ^a   Kurzrock, Razelle ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PROTEIN P53; TEMSIROLIMUS; TRAMETINIB; TUMOR MARKER;

ADULT; ARTICLE; BRAIN CANCER; BREAST CANCER; CANCER GENETICS; CANCER PATIENT; DIGESTIVE SYSTEM CANCER; FEMALE; FEMALE GENITAL TRACT CANCER; GENE MUTATION; GENOMICS; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN TISSUE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; MIDDLE AGED; MOLECULAR DIAGNOSIS; NEXT GENERATION SEQUENCING; OFF LABEL DRUG USE; PRIMARY TUMOR; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TUMOR BIOPSY; CLASSIFICATION; GENE AMPLIFICATION; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; HIGH THROUGHPUT SEQUENCING; MUTATION; NEOPLASMS; PERSONALIZED MEDICINE; PROCEDURES; STATISTICS AND NUMERICAL DATA;

BIOMARKERS, TUMOR; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASMS; PRECISION MEDICINE; RETROSPECTIVE STUDIES;

EID: 84937990975     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-1061     Document Type: Article

References (22)

1. Parkinson DR, Johnson BE, Sledge GW. Making personalized cancer medicine a reality: challenges and opportunities in the development of biomarkers and companion diagnostics. Clin Cancer Res 2012;18:619-24.
2. Munoz J, Swanton C, Kurzrock R. Molecular profiling and the reclassification of cancer: divide and conquer. Am Soc Clin Oncol Educ Book 2013;2013:127-34.
3. Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 2014;158:929-44.
4. Demetri GD, Von Mehren M, Blanke CD, Van Den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
5. Hodi FS, Friedlander P, Corless CL, Heinrich MC, MacRae S, Kruse A, et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 2008;26:2046-51.
6. Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, Stepanek VM, et al. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res 2013;73:276-84.
7. Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, et al. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep 2014;6:377-87.
8. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
9. Hofmann I, Weiss A, Elain G, Schwaederle M, Sterker D, Romanet V, et al. KRAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo. PLoS One 2012;7:e44146.
10. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006;439:358-62.
11. Westin JR, Kurzrock R. It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy. Mol Cancer Ther 2012;11:2549-55.
12. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17.
13. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-52.
14. Tsimberidou A-M, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res 2012;18:6373-83.
15. Janku F, Berry DA, Gong J, Parsons HA, Stewart DJ, Kurzrock R. Outcomes of phase II clinical trials with single-agent therapies in advanced/metastatic non-small cell lung cancer published between 2000 and 2009. Clin Cancer Res 2012;18:6356-63.
16. Said R, Hong DS, Warneke CL, Lee JJ, Wheler JJ, Janku F, et al. P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. Oncotarget 2013;4:705-14.
17. Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, et al. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist 2014;9:616-22.
18. Schwaederle M, Parker BA, Schwab RB, Fanta PT, Boles SG, Daniels GA, et al. Molecular tumor board: The University of California San Diego Moores Cancer Center Experience. Oncologist 2014;18:631-6.
19. Heinrich MC, Joensuu H, Demetri GD, Corless CL, Apperley J, Fletcher JA, et al. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res 2008;14:2717-25.
20. accessdata.fda.gov [database on the Internet]. U. S. Food and Drug Administration: imatinib package insert [updated 2015 Feb. 2; cited 2015 Feb. 2]. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2006/021588s011s012s013s014s017lbl.pdf
21. Wheler JJ, Parker BA, Lee JJ, Atkins JT, Janku F, Tsimberidou AM, et al. Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms. Oncotarget 2014;5:2349-54.
22. Vidwans SJ, Turski ML, Janku F, Garrido-Laguna I, Munoz J, Schwab R, et al. A framework for genomic biomarker actionability and its use in clinical decision making. Oncoscience 2014;1:614-23.